Stabilized single domain antibodies
AssigneeAblynx N.V.
InventorsKaren Silence, Marc Jozef Lauwereys, Torsten Dreier
Life of this patent
Estimating the term…
Abstract
The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.
Claims47
A polypeptide construct comprising a first immunoglobulin single variable domain having a first antigen or epitope binding specificity and a second immunoglobulin single variable domain having a second antigen or epitope binding specificity wherein one or both of said first and second variable domains bind to an antigen or epitope which increases the half-life of the ligand in vivo, and either (i) the first and the second immunoglobulin variable domains are heavy chain variable domains;
- or (ii) the first and the second immunoglobulin variable domains are light chain variable domains.
(canceled)
(canceled)
(canceled)
A polypeptide construct comprising an anti-human TNF alpha single domain antibody (dAb) and an anti-serum albumin (SA) dAb,
- wherein each of the anti-human TNF alpha dAb and the anti-SA dAb is a heavy chain variable domain;
- or
- wherein each of the anti-human TNF alpha dAb and the anti-SA dAb is a light chain variable domain.
A polypeptide construct comprising an anti-human TNF alpha Camelid VHH domain and an anti-serum albumin (SA) Camelid VHH domain.
-29. (canceled)
A polypeptide construct comprising a first immunoglobulin single variable domain having binding specificity for serum albumin (SA), and a second immunoglobulin single variable domain having binding specificity for an antigen selected from the group consisting of IFN-γ, tumour necrosis factor (TNF), TNF-α, and IFN-gamma-receptor,
- wherein each of the first and second single variable domains is a heavy chain variable domain;
- or
- wherein each of the first and second single variable domains is a light chain variable domain.
A polypeptide construct comprising a first immunoglobulin single variable domain having binding specificity for serum albumin (SA), and a second immunoglobulin single variable domain having binding specificity for an antigen selected from the group consisting of human or animal proteins, cytokines, cytokine receptors, and enzymes,
- wherein each of the first and second single variable domains is a heavy chain variable domain;
- or
- wherein each of the first and second single variable domains is a light chain variable domain.
(canceled)
A variable domain specific for serum albumin (SA) which has a dissociation constant (Kd) of 1 nM to 500 μM for SA, as determined by surface plasmon resonance.
-40. (canceled)
A polypeptide construct comprising a dimer, trimer or tetrameter of (i) heavy chain single variable domains or (ii) light chain single variable domains, the domains being specific for the same epitope or adjacent epitopes on the same target.
A polypeptide construct comprising (i) first and second heavy chain single variable domains or (ii) first and second light chain single variable domains, the domains having the same epitope specificity, wherein the epitope is provided as multiple copies by TNF alpha.
A polypeptide construct comprising (i) first and second heavy chain single variable domains, or (ii) first and second light chain single variable domains, wherein each domain has binding specificity to an epitope or antigen with a dissociation constant (Kd) of 1×10−7 M or less, as determined by surface plasmon resonance.
A polypeptide construct comprising (i) first and second heavy chain single variable domains, or (ii) first and second light chain single variable domains, wherein each domain has binding specificity to an antigen selected from the group consisting of human or animal proteins, cytokines, and cytokine receptors.
A polypeptide construct comprising (i) first and second heavy chain single variable domains, or (ii) first and second light chain single variable domains, wherein each domain has binding specificity to an antigen selected from the group consisting of IFN-gamma, tumour necrosis factor (TNF), TNF-alpha, and IFN gamma receptor.
(canceled)
(canceled)
Dependencies are inferred from the claim text.